Part 3 ARCHER II research of vonaprument underway in dry AMD, GA
August 17, 2025
2 min watch
LONG BEACH, Calif. — On this video from the American Society of Retina Specialists annual assembly, David A. Eichenbaum, MD, FASRS, discusses research design and rationale for the part 3 ARCHER II research.
The research is evaluating vonaprument (Annexon Biosciences) in sufferers with dry age-related macular degeneration and geographic atrophy.
“Vonaprument, which was once referred to as ANX007, has the potential to be the primary geographic atrophy remedy that would protect imaginative and prescient and permit sufferers worldwide to profit from developments within the remedy of dry macular degeneration, pending the readout of this ARCHER II scientific trial,” Eichenbaum, of Retina Vitreous Associates of Florida, advised Healio.
The research readout is predicted within the subsequent 12 to 18 months.
Sources/Disclosures
Collapse
Eichenbaum DA. ARCHER II, a part 3 randomized scientific trial of ANX007 in sufferers with dry AMD and GA: Research design and rationale knowledgeable by outcomes from ARCHER. Introduced at: American Society of Retina Specialists annual assembly; July 30-Aug. 2, 2025; Lengthy Seaside, California.
Disclosures:
Eichenbaum reviews being an investigator and advisor for Annexon Biosciences.
